ACTRN12610000813088已完成2 期
A double blinded, randomized, placebo controlled study on the effects of Recombinant Human Erythropoietin on proinflammatory cytokines expression following modified radical mastectomy in females with breast cancer stage II/III
niversity Hospital of Ioannina0 个研究点目标入组 22 人开始时间: 2010年9月29日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Female
入选标准
- •The inclusion criterion was defined as an established preoperative diagnosis of breast cancer stage II or III.
排除标准
- •(1) hemoglobin concentration>13gr/dl at presentation, (2) previous history of malignancy, (3) history of thromboembolic events, (4) history of seizures, (5) hypertension, (6) known allergy to Recombinant Human Erythropoietin , (7) patients with hepatic, renal, metabolic or endocrine disease, (8) patients receiving medications known to interfere with wound healing, (9) neoadjuvant chemotherapy, (11) recent major surgical procedure or recent history of transfusion and (12) patient’s denial to informed consent.
研究者
相似试验
已完成
不适用
Efficacy evaluation of hair tonic in healthy human subjectsCTRI/2018/03/012284ITC R D Centre82
进行中（未招募）
不适用
A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® tree polleEUCTR2006-003067-31-LTETI Pharma GmbH230
进行中（未招募）
不适用
A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® House dust mites (HDM) in patients suf-fering from moderate to severe atopic eczema.Moderate to severe atopic eczema with or without rhinitis and/or rhinoconjunctivitis caused by clinical relevant IgE-mediated sensitization against House dust mites (HDM) leading to aggravation of patient’s skin lesions.MedDRA version: 8.1Level: LLTClassification code 10003641Term: Atopic eczemaEUCTR2006-003066-34-DEETI Pharma GmbH
进行中（未招募）
不适用
A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® tree polleRhinitis and/or rhinoconjunctivitis with or without allergic asthma caused by clinical relevant sensitization against tree pollen.MedDRA version: 8.1Level: LLTClassification code 10039083Term: RhinitisEUCTR2006-003067-31-DEETI Pharma GmbH230
进行中（未招募）
不适用
A study of evaluate the efficacy and safety of investigational product Femildo(TM) in management of sexual dysfunction in womeCTRI/2019/01/016868ADSO Naturals Holdings BV24